Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults.

@article{Ledgerwood2015SafetyPA,
  title={Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults.},
  author={Julie E Ledgerwood and Emily Coates and Galina V. Yamshchikov and Jamie G. Saunders and Lasonji Holman and Mary E. Enama and Adam Dezure and R Lynch and Ingelise J. Gordon and Sarah H. Plummer and Cynthia S. Hendel and Amarendra Pegu and Michelle Conan-Cibotti and Sandra Sitar and Robert T. Bailer and Sandeep R Narpala and Adrian B McDermott and Mark K. Louder and S. P. O'dell and Sarumathi Mohan and Janardan P Pandey and Richard M. Schwartz and Zonghui Hu and Rick A Koup and Edmund Capparelli and John R. Mascola and Barney S. Graham},
  journal={Clinical and experimental immunology},
  year={2015},
  volume={182 3},
  pages={
          289-301
        }
}
VRC-HIVMAB060-00-AB (VRC01) is a broadly neutralizing HIV-1 monoclonal antibody (mAb) isolated from the B cells of an HIV-infected patient. It is directed against the HIV-1 CD4 binding site and is capable of potently neutralizing the majority of diverse HIV-1 strains. This Phase I dose-escalation study in healthy adults was conducted at the National Institutes of Health (NIH) Clinical Center (Bethesda, MD, USA). Primary objectives were the safety, tolerability and pharmacokinetics (PK) of VRC01… CONTINUE READING
BETA
Tweets
This paper has been referenced on Twitter 2 times. VIEW TWEETS

Citations

Publications citing this paper.
SHOWING 1-10 OF 62 CITATIONS

FILTER CITATIONS BY YEAR

2015
2019

CITATION STATISTICS

  • 4 Highly Influenced Citations

  • Averaged 19 Citations per year over the last 3 years

References

Publications referenced by this paper.
SHOWING 1-10 OF 45 REFERENCES

Similar Papers

Loading similar papers…